Abstract: The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.
Type:
Application
Filed:
April 1, 2020
Publication date:
June 30, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Hyuk Jun CHO, Taek KWON, Ho Taek IM, Yong ll KIM, Jin A JUNG, Han Kil SON, Sung Hee HONG
Abstract: This disclosure relates to methods for obtaining immobilized enzyme preparations, in particular to a preparation and application of a novel active conjugate of an enzyme with a polymer carrier. Said conjugate possesses the properties of the known Longidaza® drug and inhibits hyperplasia of connective tissue, and presents anti-inflammatory action, and can be used for manufacturing stable, active and safe in use long-acting drugs in the form of a suppository, ointment, injection, cosmetic cream, and for making veterinary drugs. These methods include conjugation of hyaluronidase with a water-soluble copolymer using the carbodiimide or azide conjugation method. The conjugation is carried out with the use of a copolymer N-oxide 1,4-ethylene piperazine, (N carboxymethyl)-1,4-ethylene piperazine or its hydrazide, and 1,4-ethylene piperazine of general formula: where n is from 40% to 90% of the total number of units; m is from 3% to 40% of the total number of units; and n+m+1=100%.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
June 21, 2022
Assignee:
NPO Petrovax Pharm LLC
Inventors:
Arkadii Vasilevich Nekrasov, Temuri Musaevich Karaputadze, Sergei Alekseevich Medvedev, Alexander Vladimirovich Kozukov, Nino Temurievna Karaputadze
Abstract: This present invention relates to a polymer of ?-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal. The polymer comprises a ?-glutamyl transpeptidase-responsive element represented by Formula (I). When the polymer is used as drug carrier for anticancer drug, it can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
June 21, 2022
Assignee:
HAINAN POLY PHARM CO., LTD.
Inventors:
Youqing Shen, Quan Zhou, Changhuo Xu, Jiajia Xiang
Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.
Type:
Grant
Filed:
October 1, 2018
Date of Patent:
June 14, 2022
Assignee:
HANMI PHARM. CO., LTD
Inventors:
Su Yeon Park, Ji Young Song, Eun Jung Kim, Jong Min Lee, Jong-Soo Lee, Dae Jin Kim
Abstract: Provided are crystalline forms of acid addition salts of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition including the same. The crystalline forms may be easily used in preparing the pharmaceutical composition including the same as an active ingredient.
Type:
Application
Filed:
March 20, 2020
Publication date:
June 9, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Hee Sook OH, Jae Hyuk JUNG, Ji Young JEON, Sun Young JANG, Tae Hee HA
Abstract: A carvedilol nanococrystal composition including carvedilol, a coformer, and a stabilizer. The coformer may include at least one of 3,5-dinitrobenzoicacid, gentisic acid, phloroglucinol, 4,4-bipyridine, tartaric acid, citric acid, and gallic acid. The carvedilol nanococrystal composition has a particle size of less than 5 nm, and the carvedilol has a water-solubility between about 2 mg/ml and about 10 mg/ml.
Type:
Application
Filed:
February 17, 2022
Publication date:
June 2, 2022
Applicants:
Salamat Pajoohan Parsian Pharmed
Inventors:
Gholamhossein Yousefi, Mohsen Mohammady, Mohammad Hadidi, Seyed Iman Ghetmiri
Abstract: A curcumin nanococrystal composition including curcumin, a coformer, and a stabilizer. The coformer may include at least one of 3,5-dinitrobenzoicacid, gentisic acid, phloroglucinol, 4,4-bipyridine, tartaric acid, citric acid, and gallic acid. The curcumin nanococrystal composition has a particle size less than 10 nm, and the curcumin has a water-solubility between 5 mg/ml and 20 mg/ml.
Type:
Application
Filed:
February 17, 2022
Publication date:
June 2, 2022
Applicants:
Salamat Pajoohan Parsian Pharmed
Inventors:
Gholamhossein Yousefi, Mohsen Mohammady, Seyed Iman Ghetmiri
Abstract: The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 steps of reaction, the Et-743 is synthesized. Raw materials and agents used in the synthetic route can all easily be obtained, reaction conditions are relatively mild, and preparation in large scale can be implemented.
Abstract: A solid dispersion of dutasteride for improving the solubility or dissolution rate of poorly soluble dutasteride, a method for preparing the solid dispersion, and a pharmaceutical composition including the solid dispersion are provided. The solid dispersion includes: a coprecipitate including dutasteride and a water-soluble polymeric carrier; and an adsorbent. The dutasteride and the water-soluble polymeric carrier are present in a weight ratio of 1:10-100 in the coprecipitate.
Abstract: The present invention relates to a photodynamic therapy apparatus for local targeting in cancer treatment. More specifically, an endoscope is placed in the center of an end portion of a probe used in photodynamic therapy and a plurality of optical fibers are arranged along the edge thereof, so that a lesion site is irradiated with a plurality of lights while the plurality of optical fibers of the probe receive lights from individual light sources, respectively, to perform light irradiation individually. Furthermore, the present invention relates to an apparatus, wherein unnecessary damage to normal tissues is minimized by controlling light irradiation regions, for instance, by defining light irradiation regions encompassing a lesion site from an image provided in real time through an endoscope disposed at an end portion of a probe and allowing only individual light sources irradiating the defined light irradiation regions to emit lights to achieve local light irradiation.
Type:
Application
Filed:
June 30, 2020
Publication date:
May 5, 2022
Applicant:
AMOS PHARM CO., LTD.
Inventors:
Seung Hee HAN, Brian Wilson, Jae Hyuk KIM, Sung Ho LEE
Abstract: The present invention provides a method of producing a test strip for measuring a calcium concentration in a body fluid test sample obtained from a living body (human or animal) by a colormetric change, and a test strip for measuring a calcium concentration in a human or animal body fluid test strip by a colormetric change.
Abstract: A method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof is disclosed. The method includes site-specifically binding a carrier to a protein or peptide. A protein or peptide produced by the method and the uses thereof are disclosed. The conjugate of the physiologically active protein or peptide can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.
Type:
Application
Filed:
December 30, 2021
Publication date:
April 21, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Sung Hee PARK, Seung Su KIM, Hyung Kyu LIM, Jae Hyuk CHOI, In Young CHOI, Se Chang KWON
Abstract: Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.
Type:
Application
Filed:
February 21, 2020
Publication date:
April 14, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
In Hwan BAE, Ji Sook KIM, JaeYul CHOI, Young Gil AHN
Abstract: The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.
Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
April 5, 2022
Assignee:
Hanmi Pharm. Co., Ltd.
Inventors:
In Hwan Bae, Ji Sook Kim, Jae Yul Choi, Seok Jong Kang, Young Gil Ahn, Kwee Hyun Suh
Abstract: A urine test device includes a case in which a guide is formed, a strip tray including a strip moving body formed to be slidably movable through the guide, a plurality of strip seating parts formed on the strip moving body, and a strip fixing part configured to fix the strip seated on each of the plurality of strip seating parts, a tray movement driving part configured to slidably move the strip tray, a sensing module supported by the case and including a plurality of light-emitting diodes (LEDs) configured to emit white light for testing toward the plurality of moving strips from above the plurality of strips and a plurality of image sensors configured to detect colors of the plurality of strips, and a control part configured to control the tray movement driving part to move the strip tray.
Abstract: Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.
Type:
Application
Filed:
January 31, 2020
Publication date:
March 31, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
In Hwan BAE, Won Jeoung KIM, Ji Sook KIM, Ji Young SONG, Jae Yul CHOI, Min Jeong KIM, Jung Soo NAM, Young Gil AHN
Abstract: The present invention provides a method of producing a test strip for measuring a calcium concentration in a body fluid test sample obtained from a living body (human or animal) by a colormetric change, and a test strip for measuring a calcium concentration in a human or animal body fluid test strip by a colormetric change.